Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RGL-2102 Phase II Trial in Critical Limb Ischemia
ChiCTR2500105788Phase 2Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jul 2025
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of RGL-2102 in chronic limb-threatening ischemia (CLTI) (8 cohorts), sponsored by Zhongshan Hospital, Fudan University. Primary endpoints: Change in pain score in Cohort One from baseline at Day 180 and Change in ulcer area in Cohort Two from baseline at Day 180. Started Jul 2025; status: recruiting.
02
Drugs
RGL-2102
03
Conditions
chronic limb-threatening ischemia (CLTI)
Beyond the preview
Go deeper on ChiCTR2500105788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105788.